News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 09, 2019, 09:00 ET CytRx Corporation Reports Second Quarter 2019 Financial Results

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today announced...


Jul 30, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted...


Jul 22, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol...


Jun 26, 2019, 09:00 ET CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been...


Jun 19, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that...


May 31, 2019, 09:00 ET CytRx Corporation to Commence Trading on OTCQB Venture Market

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will...


May 15, 2019, 09:00 ET CytRx Corporation Reports First Quarter 2019 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


May 08, 2019, 09:00 ET CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been...


May 02, 2019, 09:00 ET CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that...


Apr 29, 2019, 09:00 ET CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol...


Mar 29, 2019, 09:00 ET CytRx Corporation Reports 2018 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


Mar 12, 2019, 09:00 ET CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its...


Feb 13, 2019, 09:00 ET CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned...


Feb 11, 2019, 09:00 ET CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an...


Feb 06, 2019, 09:00 ET CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3...


Jan 14, 2019, 09:00 ET CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin ...


Dec 21, 2018, 09:00 ET CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private,...


Nov 28, 2018, 09:00 ET CytRx Corporation to Present at the 11th Annual LD Micro Main Event

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that John Caloz,...


Nov 08, 2018, 09:00 ET CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted two poster...


Nov 02, 2018, 09:00 ET CytRx Corporation Reports Third Quarter 2018 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results...


Oct 31, 2018, 09:00 ET Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that key emerging...


Oct 29, 2018, 09:00 ET CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report...


Sep 25, 2018, 09:00 ET CytRx Corporation to Present at the 2018 MicroCap Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric...


Sep 13, 2018, 09:00 ET CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received a...


Aug 27, 2018, 09:00 ET CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric...